OMass Therapeutics raises $310 million to push OMS1620 toward phase 2
OMass Therapeutics has secured a $310 million series C round, a financing that gives the Oxford company room to move its lead candidate, OMS1620, through phase 1 and into phase 2 development in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For a biotech that only recently remained in preclinical territory, the raise marks a sharp shift in credibility, not just capitalization. It also gives the company a wider berth to build the clinical and operational muscle needed for a program that now has to answer a harder question: can a receptor antagonist with strong target engagement translate into meaningful endocrine control in patients who live with chronic hormone excess?
The financing comes with heavyweight backing. Bain Capital Life Sciences, Forbion and Novo Holdings co-led the round, while Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences joined existing supporters including Syncona, Sanofi Ventures, the U.K. government’s British Business Bank, the University of Oxford and GV. The investor mix matters because endocrine drug development rewards patience, pharmacology and disciplined clinical execution. OMass is now positioned to spend on all three.
The lead asset sits in a clinically familiar but difficult space. Congenital adrenal hyperplasia disrupts cortisol production, which removes the normal negative feedback signal to the pituitary and drives adrenocorticotropic hormone, or ACTH, into overdrive. In practical terms, the disease forces the adrenal axis into a chronic state of compensatory overstimulation. A therapy aimed at the melanocortin-2 receptor seeks to intercept that signal where it matters most, at the receptor level, instead of trying to chase the downstream biochemical consequences after they have already taken hold.
OMS1620 has so far reached only the single-ascending-dose portion of its phase 1 study, but the company says the compound has generated encouraging early signals. The appeal is mechanistic as much as clinical. In healthy volunteers, a hormone challenge can stress the pathway and provide a clean readout of whether receptor blockade holds up when the natural ligand is present in surging concentrations. For a target tied to a daily endocrine rhythm, that type of challenge experiment is unusually informative. It can reveal whether a compound remains bound long enough to matter when ACTH rises through the day, which is exactly the pharmacologic problem a competitive antagonist has to solve.
One sentence captures the central bet here: OMS1620 appears designed to stay on the receptor long enough to outlast hormonal surges.
Ros Deegan, OMass’ chief executive, described the compound as “sticky on the receptor,” a property she linked to sustained inhibition even as ACTH levels fluctuate. That binding behavior is not just a formulation detail. In endocrine disease, target residence time can shape whether a drug merely suppresses a pathway in a controlled experimental window or maintains enough blockade to change biology over the full day. If the receptor remains occupied through physiologic peaks, the drug has a better chance of damping the feedback loop that perpetuates hormone excess in patients with CAH.
The company also sees a path into ACTH-dependent Cushing’s syndrome, where the same receptor biology may support a second indication. That dual-program logic is attractive because it concentrates capital around a validated hormonal axis rather than spreading it across disconnected mechanisms. OMass is effectively arguing that a single pharmacologic node can address multiple diseases of endocrine overdrive if the receptor is both biologically relevant and druggable enough. The financing buys time to test that premise properly.
The series C also supports a second, earlier-stage program: a preclinical SLC15A4 inhibitor being developed for lupus and other disorders tied to interferon overproduction and pathogenic B-cell activation. Here, the company is leaning into a more upstream autoimmune strategy. By modulating a node involved in inflammatory signaling and B-cell behavior, the program aims to influence the immune cascade before it blooms into tissue damage. The idea has clear industry resonance because other developers have pursued B-cell-directed approaches with cell therapies, but OMass is betting that a small molecule may offer a more practical route if it can deliver a once-daily oral option.
Deegan drew a direct line between the company’s MC2 program and the SLC15A4 effort: both are built around going after what OMass believes is the best node in a clinically validated pathway. That logic is attractive because it minimizes the risk of chasing targets with elegant biology but weak translational backing. In the current autoimmune field, the appeal of an oral small molecule is obvious. CAR-T approaches have attracted attention, but recent readouts for some of those programs have been less compelling than early enthusiasm suggested, and durable immunologic remissions remain hard to deliver safely across broad populations.
OMass’ platform traces back to the University of Oxford laboratory of Professor Carol Robinson, and the company has already begun to prove that the model can attract external validation. Genentech previously paid $20 million upfront to license OMass’ preclinical inflammatory bowel disease program, a deal that showed the platform could support partnered assets without forcing the company to surrender its strategic center of gravity. Deegan has been explicit about preserving optionality. The goal is to secure high-quality partnerships while avoiding unnecessary dilution of the company’s most valuable biology.
The new money is also about infrastructure. OMass plans to expand development capabilities as it moves deeper into clinical work and becomes more geographically distributed. The company already established a U.S. presence in 2024, and Deegan said the financing should help attract top talent on both sides of the Atlantic. That kind of buildout is not cosmetic. Once a company crosses from early clinical testing into phase 2, the demands on regulatory strategy, program management and translational interpretation increase quickly. A lean organization can generate data; a larger one has to convert data into a development path.
Deegan stopped short of signaling any near-term public-market ambition. For now, OMass is focused on moving its assets to the next set of clinical milestones with the capital it has just raised. That leaves the company with a simple but exacting task: show that receptor pharmacology can become patient benefit, first in endocrine disease and then, if the autoimmune biology holds, in lupus and related conditions. The next readouts will determine whether the financing becomes a springboard to approval-path development or merely an expensive proof of ambition.